Seres Therapeutics vs Aevice Health

Side-by-side comparison of AI visibility scores, market position, and capabilities

Aevice Health leads in AI visibility (37 vs 26)
Seres Therapeutics logo

Seres Therapeutics

GrowthBiotechnology

Microbiome Medicine

Seres Therapeutics develops microbiome therapeutics, including Vowst, the first FDA-approved oral microbiome medicine for preventing recurrent C. difficile infection.

AI VisibilityBeta
Overall Score
D26
Category Rank
#1 of 1
AI Consensus
51%
Trend
up
Per Platform
ChatGPT
17
Perplexity
35
Gemini
37

About

Seres Therapeutics is a publicly traded clinical-stage biopharmaceutical company founded in 2012 that pioneered the development of microbiome therapeutics, medicines derived from human gut microbiota. The company's lead product Vowst received FDA approval in 2023 as the first oral microbiome therapeutic, consisting of purified fecal microbiota spores administered as capsules to prevent recurrent Clostridioides difficile infection after antibiotic treatment. C. difficile infects hundreds of thousands of Americans annually and has high recurrence rates that existing antibiotics cannot fully prevent. Vowst works by restoring a diverse, healthy gut microbiome that can resist C. difficile colonization. Seres has partnered with Nestlé Health Science for US commercialization and is developing pipeline programs for inflammatory bowel disease, oncology supportive care, and other conditions where the gut microbiome plays a pathological role. The company's success with Vowst validated the regulatory pathway for microbiome therapeutics and established Seres as the pioneer of an emerging therapeutic class with broad potential across gastrointestinal and systemic diseases.

Full profile
Aevice Health logo

Aevice Health

EmergingBioTech

Digital Health

Aevice Health raised $30M Series B in 2025 for its AI-powered wearable respiratory monitor that continuously tracks wheezing, coughing, and breathing abnormalities in asthma and COPD patients.

AI VisibilityBeta
Overall Score
D37
Category Rank
#1 of 1
AI Consensus
65%
Trend
up
Per Platform
ChatGPT
43
Perplexity
46
Gemini
43

About

Aevice Health develops wearable respiratory monitoring technology that uses AI to analyze breath sounds captured continuously from a chest-worn device. The AeviceMD system detects wheezing, coughing, and abnormal breathing patterns in real time, enabling early warning of asthma attacks and COPD exacerbations before they require emergency care. The device transmits data to a smartphone app and clinical dashboard for remote monitoring by pulmonologists.

Full profile

AI Visibility Head-to-Head

26
Overall Score
37
#1
Category Rank
#1
51
AI Consensus
65
up
Trend
up
17
ChatGPT
43
35
Perplexity
46
37
Gemini
43
35
Claude
32
29
Grok
36

Key Details

Category
Microbiome Medicine
Digital Health
Tier
Growth
Emerging
Entity Type
brand
brand

Capabilities & Ecosystem

Capabilities

Only Seres Therapeutics
Microbiome Medicine
Only Aevice Health
Digital Health

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.